November 2, 2021
Ono Pharmaceutical rang up a double-digit increase in its April-September revenue over the same period a year earlier, driven by its PD-1 inhibitor Opdivo (nivolumab), which expanded volume sales to more than counter a 10%-plus price cut implemented in August...read more